Drug intelligence / Profile preview

HS-20108

Development stage: Phase 1
Lead developer: Hansoh BioMedical
Administration: Intravenous

Overview

HS-20108 is an **investigational biological product** developed by Shanghai Hansoh Biomedical, specifically as an intravenous therapy for advanced malignant solid tumors. The drug has entered Phase 1 clinical trials, and its mechanism of action, precise molecular target, and detailed modality remain undisclosed in public registries. The clinical research is focused on assessing its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with various advanced solid tumors, with particular interest in subtypes such as small cell lung cancer and neuroendocrine carcinoma. As of the latest updates, HS-20108 is not approved for any indication and remains in early clinical development[1][2][3][4][7][9][10].

Brand names: HS-20108HS20108HS 20108
Other names: HS-20108HS20108HS 20108

Beyond the preview

Go deeper on HS-20108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-20108.

Explore the full profile